secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcturus Therapeutics Holdings Inc. (ARCT)
CIK:        0001768224
Form:       8-K
Filed at:   2025-05-12T23:59:59+00:00
Accession:  0001193805-25-000630
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcturus Q1 net loss narrows to $14.1M; cash runway extends into 2028
---------------------------------------------------------------------

- Net loss $14.1M ($0.52/diluted share) vs $26.8M ($1.00) a year ago; revenue $29.4M down 23% YoY.
- Cash, equivalents and restricted cash $273.8M at March 31, 2025; runway extended into 2028 via resource re-allocation.
- Received initial EU approval milestone payment from CSL Seqirus for KOSTAIVE COVID-19 vaccine.
- ARCT-032 (CF) Phase 2 interim data from first two cohorts expected mid-2025; enrollment to complete by year-end.
- ARCT-810 (OTC) Phase 2 interim data expected Q2 2025; FDA Fast Track granted for H5N1 vaccine ARCT-2304.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768224/000119380525000630/0001193805-25-000630-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768224/000119380525000630/e664482_8k-arct.htm
  HTML page:      https://secwatch.observer/filing/0001193805-25-000630

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer